Peng KW - Search Results

1

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.

Peng KW, Carey T, Lech P, Vandergaast R, Muñoz-Alía MÁ, Packiriswamy N, Gnanadurai C, Krotova K, Tesfay M, Ziegler C, Haselton M, Sevola K, Lathrum C, Reiter S, Narjari R, Balakrishnan B, Suksanpaisan L, Sakuma T, Recker J, Zhang L, Waniger S, Russell L, Petro CD, Kyratsous CA, Baum A, Janecek JL, Lee RM, Ramachandran S, Graham ML, Russell SJ. Peng KW, et al. Vaccine. 2022 Apr 1;40(15):2342-2351. doi: 10.1016/j.vaccine.2021.12.063. Epub 2022 Jan 10. Vaccine. 2022. PMID: 35282925 Free PMC article.

2

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.

Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Peng KW, et al. Nat Med. 2002 May;8(5):527-31. doi: 10.1038/nm0502-527. Nat Med. 2002. PMID: 11984600

3

Intraperitoneal therapy of ovarian cancer using an engineered measles virus.

Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Peng KW, et al. Cancer Res. 2002 Aug 15;62(16):4656-62. Cancer Res. 2002. PMID: 12183422

4

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Peng KW, et al. Blood. 2003 Apr 1;101(7):2557-62. doi: 10.1182/blood-2002-07-2195. Epub 2002 Nov 14. Blood. 2003. PMID: 12433686 Free article.

5

Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.

Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Phuong LK, et al. Among authors: peng kw. Cancer Res. 2003 May 15;63(10):2462-9. Cancer Res. 2003. PMID: 12750267

6

Primer on medical genomics. Part X: Gene therapy.

Russell SJ, Peng KW. Russell SJ, et al. Among authors: peng kw. Mayo Clin Proc. 2003 Nov;78(11):1370-83. doi: 10.4065/78.11.1370. Mayo Clin Proc. 2003. PMID: 14601696 Review.

7

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Dingli D, et al. Among authors: peng kw. Blood. 2004 Mar 1;103(5):1641-6. doi: 10.1182/blood-2003-07-2233. Epub 2003 Nov 6. Blood. 2004. PMID: 14604966 Free article.

8

Antibody-targeted cell fusion.

Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T, Cattaneo R, Russell SJ. Nakamura T, et al. Among authors: peng kw. Nat Biotechnol. 2004 Mar;22(3):331-6. doi: 10.1038/nbt942. Epub 2004 Feb 15. Nat Biotechnol. 2004. PMID: 14990955

9

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.

Anderson BD, Nakamura T, Russell SJ, Peng KW. Anderson BD, et al. Among authors: peng kw. Cancer Res. 2004 Jul 15;64(14):4919-26. doi: 10.1158/0008-5472.CAN-04-0884. Cancer Res. 2004. PMID: 15256464

10

Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.

Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Allen C, et al. Among authors: peng kw. J Gene Med. 2004 Nov;6(11):1216-27. doi: 10.1002/jgm.616. J Gene Med. 2004. PMID: 15459967

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

182 results

Search Page